Janux Therapeutics (JANX) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Janux will report Q1 2026 results before the market opens on May 14, with analysts forecasting EPS of ($0.5202) and revenue of $4.357 million; an earnings call is scheduled for May 15 at 4:00 PM ET.
• In the prior quarter Janux beat expectations, reporting EPS of ($0.51) versus consensus ($0.65) and revenue of $7.88 million versus estimates of $0.08 million, highlighting volatile results versus estimates.
• The stock trades near $14.62 with a market cap of $891 million, while analyst sentiment is mixed—average rating "Moderate Buy" and an average price target of $49.75—even as several firms have recently cut price targets (e.g., UBS to $15).

Janux Therapeutics (NASDAQ:JANX - Get Free Report) is projected to issue its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.5202) per share and revenue of $4.3570 million for the quarter. Parties can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.51) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.14. The firm had revenue of $7.88 million for the quarter, compared to analyst estimates of $0.08 million. On average, analysts expect Janux Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Janux Therapeutics Price Performance

Janux Therapeutics stock opened at $14.62 on Thursday. The stock's 50 day moving average is $14.34 and its 200 day moving average is $17.53. The firm has a market cap of $891.26 million, a P/E ratio of -7.99 and a beta of 2.58. Janux Therapeutics has a one year low of $12.12 and a one year high of $35.34.

Analyst Ratings Changes

JANX has been the topic of a number of recent analyst reports. Weiss Ratings raised Janux Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, April 22nd. Clear Str lowered Janux Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, January 20th. JonesTrading cut their price objective on Janux Therapeutics from $50.00 to $28.00 and set a "buy" rating on the stock in a research note on Tuesday, April 28th. Cantor Fitzgerald cut their price objective on Janux Therapeutics from $150.00 to $100.00 and set an "overweight" rating on the stock in a research note on Friday, February 27th. Finally, UBS Group lowered Janux Therapeutics from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $57.00 to $15.00 in a research note on Wednesday, April 15th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $49.75.

Institutional Investors Weigh In On Janux Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. increased its holdings in Janux Therapeutics by 15.7% in the fourth quarter. Invesco Ltd. now owns 28,322 shares of the company's stock worth $391,000 after purchasing an additional 3,853 shares in the last quarter. XTX Topco Ltd bought a new stake in Janux Therapeutics in the fourth quarter worth approximately $2,228,000. Virtus Investment Advisers LLC increased its holdings in Janux Therapeutics by 290.6% in the fourth quarter. Virtus Investment Advisers LLC now owns 17,388 shares of the company's stock worth $240,000 after purchasing an additional 12,936 shares in the last quarter. Wellington Management Group LLP increased its holdings in Janux Therapeutics by 129.5% in the fourth quarter. Wellington Management Group LLP now owns 1,610,186 shares of the company's stock worth $22,221,000 after purchasing an additional 908,582 shares in the last quarter. Finally, Twinbeech Capital LP bought a new stake in shares of Janux Therapeutics during the fourth quarter valued at approximately $812,000. 75.39% of the stock is currently owned by institutional investors.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.